Based on this broad pre-clinical basis for efficacy, G-CSF is now undergoing testing in clinical trials by three different groups, primarily aimed at demonstrating safety in human stroke patients (reviewed in [16]). This evidence concerns the gene CSF3 and stroke disorder.